Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement

Thrombosis Research

Volumn 120, Issue 5, 2007, Pages 685-693

  Eriksson, Bengt I ^a   Borris, Lars C ^b   Dahl, Ola E ^c   Haas, Sylvia ^d   Huisman, Menno V ^e   Kakkar, Ajay K ^c,f   Misselwitz, Frank ^g   Muehlhofer, Eva ^g   Kälebo, Peter ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g BAYER PHARMA AG   (Germany)

Author keywords

BAY 59 7939; Deep vein thrombosis; Factor Xa inhibitors; Hip replacement surgery; Oral anticoagulant; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; RIVAROXABAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTRIC ULCER BLEEDING; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATIONS; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 34250651947     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.12.025     Document Type: Article

References (14)

1. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338S-400S
2. Ansell J., and Bergqvist D. Current options in the prevention of thromboembolic disease. Drugs 64 (2004) 1-5
3. Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk 2000. The European Agency for the Evaluation of Medicinal Products. London, UK: CPMP/EWP/707/98.
4. Dahl O.E. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 64 Suppl 1 (2004) 17-25
5. Leadley Jr. R.J. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 1 (2001) 151-159
6. Weitz J.I., and Bates S.M. New anticoagulants. J Thromb Haemost 3 (2005) 1843-1853
7. Perzborn E., Strassburger J., Wilmen A., Pohlmann J., Roehrig S., Schlemmer K.H., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 3 (2005) 514-521
8. Kubitza D., Becka M., Voith B., Zuehlsdorf M., and Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78 (2005) 412-421
9. Kubitza D., Becka M., Wensing G., Voith B., and Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61 (2005) 873-880
10. 14C]BAY 59-7939 - an oral, direct Factor Xa inhibitor - in rat, dog and human. Drug Metab Rev 36 Suppl 1 (2004) 98 (Abstract 196)
11. Rabinov K., and Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 104 (1972) 134-144
12. Kalebo P., Ekman S., Lindbratt S., Eriksson B.I., Pauli U., Zachrisson B.E., et al. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost 76 (1996) 893-896
13. Eriksson B.I., Agnelli G., Cohen A.T., Dahl O.E., Lassen M.R., Mouret P., et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 1 (2003) 2490-2496
14. Eriksson B.I., Dahl O.E., Buller H.R., Hettiarachchi R., Rosencher N., Bravo M.L., et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3 (2005) 103-111